Clinical trial Recruiting at 1 site Observational Ages 18 to 80

PENG nerve block with or without pulsed radiofrequency for chronic hip osteoarthritis pain

Official title: Evaluation of the Clinical Effectiveness of Pericapsular Nerve Group (PENG) Block and Pulsed Radiofrequency Applications in Chronic Hip Pain

Run by Ankara City Hospital Bilkent · NCT07360093 · Data updated 2026-11-12

The study will try adding pulsed radiofrequency to a PENG nerve block to see if it reduces pain for longer in people with chronic hip osteoarthritis who still have significant pain despite conservative treatment.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment84 (estimated)
SponsorAnkara City Hospital Bilkent
Academic / other
Locations1 site (Ankara)
StatusRecruiting
StartedFebruary 1, 2026
Main results expectedFebruary 1, 2027
Study endsFebruary 28, 2027
Registry record updatedMarch 18, 2026
Trial IDNCT07360093 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with chronic hip pain for at least three months due to clinical or radiographic hip osteoarthritis, baseline VAS score of 4 or higher, and inadequate response to conservative treatments are ideal candidates.

Probably not a fit

Patients with hip pain from malignancy, prior hip arthroplasty, active local or systemic infection, uncorrectable coagulopathy or inability to stop anticoagulants, severe neurological deficit, or who are pregnant or breastfeeding are unlikely to benefit or are excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational comparison of two interventional approaches for chronic hip osteoarthritis pain: ultrasound-guided pericapsular nerve group (PENG) block alone versus PENG block combined with pulsed radiofrequency (PRF). The primary outcome is change in pain intensity measured by the Visual Analog Scale, and secondary outcomes include hip function assessed with validated functional scales. Eligible patients are adults with chronic hip pain lasting at least three months, baseline VAS ≥4, and inadequate response to conservative care. Procedures are performed at a single center with follow-up to determine whether adding PRF yields longer-lasting analgesia and functional benefit.

Why it matters

Potential benefit: If successful, adding PRF to the PENG block could provide longer-lasting pain relief and better hip function, reducing the need for repeat procedures and improving daily activities.

How similar studies have gone: Previous small studies show PENG blocks provide short-term pain relief and PRF has produced promising results in other joint pain settings, but combining PENG with PRF has limited published data and remains relatively untested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Presence of chronic hip pain lasting at least 3 months
* Baseline Visual Analog Scale (VAS) score ≥ 4
* Clinical and/or radiological diagnosis of hip osteoarthritis
* Inadequate response to conservative treatments

Exclusion Criteria:

* Local or systemic infection at the intervention site
* Coagulopathy or inability to discontinue anticoagulant therapy
* Hip pain related to malignancy
* History of previous hip arthroplasty
* Severe neurological deficit
* Pregnancy or breastfeeding

Where it's running

  • Ankara Bilkent City Hospital
    Ankara, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.